 Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F Biofrontera or the Company, an international biopharmaceutical company, has signed today an exclusive license agreement the Agreement with Maruho Co, Ltd, Osaka, Japan Maruho for the development and commercialization of Ameluz for all indications in East Asia and Oceania, based on the term sheet agreed on March 3, 2020 see ad hoc release of March 3, 2020. Under the terms of the Agreement, Maruho will obtain exclusive development and commercialization rights including the right to sublicense for Ameluz in Japan, China, Korea, India, Pakistan, Vietnam, the Philippines, Australia, New Zealand as well as the surrounding countries and islands the Territory. 